Basal insulin intensification after tirzepatide led to clinically significant HbA1c improvements in adults with diabetes who had inadequate glycemic control. The study in Diabetes Therapy evaluated insulin glargine 300 U/mL (Gla-300) in T2DM after insufficient HbA1c reduction with tirzepatide.

The DELIVER-T analysis used retrospective U.S. Optum Clinformatics data from 2022 to 2024. Eligible adults were insulin-naïve, had T2DM, and previously received tirzepatide before switching to or adding Gla-300. The primary analysis focused on individuals with a baseline HbA1c >7.0%. The primary endpoint was HbA1c change at 6 months, and secondary endpoints included achieving HbA1c <7.0% and hypoglycemia.

Eighty-two adults met criteria for the primary analysis. Mean HbA1c decreased by 1.3% over 6 months, and 26.8% achieved an HbA1c below 7.0%. No hypoglycemia events were identified in the database during follow-up.

These findings support the effectiveness of Gla-300 intensification after suboptimal HbA1c response to tirzepatide in adults with T2DM.